Response of adenocarcinoma of the uterine cervix to chemoradiotherapy
- Authors:
- Orit Kaidar-Person
- Sawsan Yosefia
- Roxolyana Abdah-Bortnyak
View Affiliations
Affiliations: Division of Oncology, Rambam Health Care Campus, Haifa 31096, Israel
- Published online on: April 8, 2015 https://doi.org/10.3892/ol.2015.3105
-
Pages:
2791-2794
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the current retrospective study was to investigate the response of advanced cervical adenocarcinoma (AC) to definitive chemoradiotherapy. Uterine cervical cancer is one of the most common cancer types among females, with squamous cell carcinoma (SQCC) being the most prevalent histological type. The incidence of cervical AC and its variants has markedly increased in recent decades. The current understanding with regard to the treatment of cervical cancer has been established through studies in which the majority of the patients suffered from SQCC, while only a limited number of studies have focused on the treatment of AC. Therefore, the optimal treatment for uterine cervical AC remains unclear. In the present study, data were collected from the medical files of patients who were diagnosed with advanced uterine cervical AC and treated with chemoradiotherapy between 1998 and 2013. Data were also collected from a group of patients with SQCC for comparison with AC patients in terms of response and survival. A total of 68 uterine cervical cancer cases were included, including 29 AC patients and 39 SQCC patients. Compared with the SQCC subgroup, a higher number of AC patients required surgery following chemoradiotherapy due to a lack of response to the initial treatment (5% vs. 31%, respectively; P=0.0065). After a median follow‑up period of 10 years, patients with AC exhibited shorter overall survival (7.4 years vs. 11 years for AC and SQCC groups, respectively; P=0.01). Differences in recurrence (40.7% vs. 34.4%; P=0.79) and disease‑free interval (1.2 years vs. 2 years; P=0.11) were not statistically significant. The results indicated that cervical AC is less responsive to chemoradiotherapy compared with SQCC.
View References
|
1
|
Fujiwara K, Monk B and
Devouassoux-Shisheboran M: Adenocarcinoma of the uterine cervix:
why is it different? Curr Oncol Rep. 16:4162014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eifel PJ, Burke TW, Morris M and Smith TL:
Adenocarcinoma as an independent risk factor for disease recurrence
in patients with stage IB cervical carcinoma. Gynecol Oncol.
59:38–44. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith HO, Tiffany MF, Qualls CR and Key
CR: The rising incidence of adenocarcinoma relative to squamous
cell carcinoma of the uterine cervix in the United States - a
24-year population-based study. Gynecol Oncol. 78:97–105. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen JL, Huang CY, Huang YS, et al:
Differential clinical characteristics, treatment response and
prognosis of locally advanced adenocarcinoma/adenosquamous
carcinoma and squamous cell carcinoma of cervix treated with
definitive radiotherapy. Acta Obstet Gynecol Scand. 93:661–668.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lacey JV Jr, Swanson CA, Brinton LA, et
al: Obesity as a potential risk factor for adenocarcinomas and
squamous cell carcinomas of the uterine cervix. Cancer. 98:814–821.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang YT, Wang CC, Tsai CS, et al:
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous
carcinoma of cervix treated by radical hysterectomy and adjuvant
radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys.
84:420–427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wakatsuki M, Kato S, Ohno T, et al:
Working Group of the Gynecological Tumor: Clinical outcomes of
carbon ion radiotherapy for locally advanced adenocarcinoma of the
uterine cervix in phase 1/2 clinical trial (protocol 9704). Cancer.
120:1663–1669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee MY, Wu HG, Kim K, Ha SW, Kim JS, Kim
IA and Lee HP: Concurrent radiotherapy with paclitaxel/carboplatin
chemotherapy as a definitive treatment for squamous cell carcinoma
of the uterine cervix. Gynecol Oncol. 104:95–99. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al: CROSS
Group: Preoperative chemoradiotherapy for esophageal or junctional
cancer. N Engl J Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Menkarios C, Azria D, Laliberté B,
Moscardo CL, Gourgou S, Lemanski C, et al: Optimal organ-sparing
intensity-modulated radiation therapy (IMRT) regimen for the
treatment of locally advanced anal canal carcinoma: a comparison of
conventional and IMRT plans. Radiat Oncol. 2:412007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldie SJ, Gaffikin L, Goldhaber-Fiebert
JD, et al: Alliance for Cervical Cancer Prevention Cost Working
Group: Cost-effectiveness of cervical-cancer screening in five
developing countries. N Engl J Med. 353:2158–2168. 2005. View Article : Google Scholar : PubMed/NCBI
|
